Dan Baker

Dan Baker is a physician-scientist turned biotech founder who spent two decades at Johnson & Johnson's Janssen division helping bring immunology blockbusters Remicade, Simponi and Stelara to patients, before launching Brisbane-based Kira Biotech in 2019 as its founding CEO. Kira is developing KB312, a first-in-class antibody designed to selectively retrain the immune system rather than broadly suppress it, aimed at autoimmune diseases such as rheumatoid arthritis, lupus and type 1 diabetes. A rheumatologist who taught at the University of Pennsylvania for 18 years, Baker also advises drug-development organisations and serves as a healthcare venture partner.